Active Ingredient(s): Venetoclax
FDA Approved: * April 11, 2016
Pharm Company: * ABBVIE INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Venclexta Overview

Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML).[3][4] The most common side effects are low levels of neutrophils (a type of white blood cell), diarrhea, nausea, anemia (low red blood cell counts), nose and throat infection and tiredness.[4] Venetoclax attaches to a protein called Bcl-2.&...

Read more Venclexta Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Venclexta Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet: 100mg, 10mg, 50mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Venclexta: (4 results)

Sorted by National Drug Code
  • 0074-0561 Venclexta 10 mg Oral Tablet, Film Coated by Abbvie Inc.
  • 0074-0566 Venclexta 50 mg Oral Tablet, Film Coated by Abbvie Inc.
  • 0074-0576 Venclexta 100 mg Oral Tablet, Film Coated by Abbvie Inc.
  • 0074-0579 Venclexta Kit by Abbvie Inc.

Other drugs which contain Venetoclax or a similar ingredient: (1 result)